Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | EDNRB | P24530 | 3/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915244 | 1.00 | REN (0.37) | RENEDNRBTHRBALDH1A1CYP3A4 | |
| SCHEMBL1039229 | 0.90 | REN (0.38) | RENEDNRBTHRBALDH1A1CYP3A4 | |
| SCHEMBL3904690 | 0.90 | REN (0.37) | RENEDNRBTHRBALDH1A1CYP3A4 | |
| SCHEMBL1035197 | 0.89 | REN (0.38) | RENEDNRBTHRBALDH1A1CYP3A4 | |
| SCHEMBL13941502 | 0.89 | REN (0.39) | RENTHRBALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL1040340 | 0.88 | REN (0.37) | RENEDNRBTHRBALDH1A1CYP3A4 | |
| SCHEMBL5069719 | 0.88 | REN (0.38) | RENTHRBALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL3902420 | 0.88 | REN (0.38) | RENTHRBALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL1038578 | 0.88 | REN (0.37) | RENTHRBALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL1040648 | 0.88 | REN (0.37) | RENTHRBALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| EP-2018862-A1 | Substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2009-01-28 | — | — | EP | disclosed |
| EP-1973903-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | Speedel Experimenta AG (CH) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007082907-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029981-A1 | SUBSTITUTED 4-PHENYLPIPERIDINES | REN, AGTR2, ACE | REN 1/4885EDNRB 256/4885THRB 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.